The world needs Elite's ELI product line. Prince died due to an overdose on Percocet, an addictive pain-killer that relieves moderate to severe pain, combining acetaminophen and oxycodone. This followed after he underwent hip surgery in 2010.

Saving my "Cheers!" after the FDA approves ELI-200.

You, folks, do know that I am spreading out my contribution throughout the year; instead of making one big purchase.

Cheers!

Investing $5500 in my Roth IRA and another $5500 in my Roth 401k for ELTP.

Cheers!

Get ready to read more ELTP conspiracy theories that focus only on the share price as we move closer to July. The real value of the stock has not been priced in until we hear from the FDA.

Cheers!

Always value great advice. In another week it would be May, and just a couple more months before the fireworks begin.

Cheers!

Woke up to a green ELTP.

Cheers!

Elite will be great under Hakim while the USA under Bush and Obama not so great.

Cheers!

Sorry, on a daily basis, the stock price action plus reasonable volume never moves in a straight line but oscillates. As a point of reference, one would need to take today's daily closing price in relation to the 30-day, 3-months, 6-months, and annual charts to formulate a better perspective that shares bought below 25-cents have a respectable gain.

Cheers!

Indeed, he will make Elite great with careful and precise planning. ELI-200 is for starters.

Cheers!

Humanwell folks might be buying???

Cheers?

Changes to their Board of Directors
Gene Pfeifer Joins Elite’s Board
Elite Pharmaceuticals, Inc.
April 12, 2016 8:00 AM
GlobeNewswire

OTC BBTue, Apr 12, 2016 3:59 PM EDT

ELITE PHARMACEUTICALS INC /NV/ Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements an EDGAR Online 1 day 1 hr ago
Elite Pharmaceuticals, Inc. :ELTP-US: Earnings Analysis: Q3, 2016 By the Numbers Capital Cube q 6 days ago
More
NORTHVALE, N.J., April 12, 2016 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) announced today that its Board of Directors has appointed Eugene Pfeifer to its board effective April 7, 2016. At the same meeting, the Board accepted the resignation of Jeenarine Narine.

Mr. Pfeifer brings with him more than 45 years of regulatory and trade experience, most recently having served as a law partner at King & Spalding in Washington DC and prior to that as a law partner at the Burditt, Bowles & Radzius. Among his many accomplishments, he was a major participant in the development of the Drug Price Competition and Patent Term Restoration Act of 1984, and provided strategic counseling to companies affected by that statue. In addition, he has provided regulatory advice and representation on a wide variety of FDA, FTC, and DEA regulated activities, including product approval, advertising, promotion, and compliance issues.

Prior to working at Burditt, Bowles and Radzius, Mr. Pfeifer served for a year in the General Counsel’s office of the Federal Trade Commission, where he represented the FTC in Federal Court to enjoin violations of the Federal Trade Commission Act, and served ten years in the Chief Counsel’s Office at the FDA as Associated Chief Counsel for Enforcement, Associate Chief Counsel for Drugs and Deputy Chief Counsel for Regulations and Hearings. During his tenure at the FDA, he was the FDA’s lead litigator and Appellate Court advocate, and he briefed the FDA’s cases before the Supreme Court. Mr. Pfeifer is a graduate of Brown University and the Georgetown University Law Center.

Mr. Narine tendered his resignation as part of the acquisition of Epic Pharma LLC by Humanwell Healthcare USA, LLC. Mr. Narine is one of the founding members of Epic Pharma.

“We welcome Gene to our board,” said Elite’s Chairman of the Board, Nasrat Hakim. “He will be a great addition for us and brings tremendous experience and expertise to Elite. I also want to thank Jai Narine for his years of contributions to Elite during a period of change and growth.”

Cheers!

Yes sir, my investment in Elite is a lock for the long-term. It is never too late to buy shares.

Cheers!

Cheers!

MAHALOS for advice! Avoiding debt and "maxing" my company's 401k, too, until retirement.

Cheers!

Looking to max my Roth IRA with a buy order for $5,500 worth of shares in 2016.

Cheers!

Lol, you cannot score if the ball is dropped. Otherwise, there would be no major obstacles from scoring touchdowns investing on ELTP if you have patience and discipline. Elite has demonstrated to be the real-deal when it comes to being a legitimate company. Sometimes the most formidable opponent would be the investor's own self.

Cheers!

I think Lasers meant to observe ELTP in the long-term. ELTP might close down today, but there is the expectations of the FDA-approval for ELI-200, NDAs, and revenue gains.

Cheers!

If you do the math, $0.87 - $0.125 = $0.74. Not savvy investing to say the least, Aqua would be kicking her butt for missing the opportunity to "flip" shares that gained in value of $0.74.

Cheers!

This is a high risk, high reward/loss stock. If your invested, expect to have your daily dose of being beaten up. I overestimated this stock to fall around 2-cents. Now, I sense the sub-pennies is where AMBS should be valued. I do own a very few shares.

Good luck and Cheers!

I had questions that were answered and some with no replies. Not even an "Thank you for your interest in Elite". She must be busy making coffee and answering phone calls for executives. They sure need to hire an assistant for Diane.

Cheers!

ELTP oscillates up and down, and not one directional. Elite is thriving on the basis of its diversified drug pipeline, which is earning record breaking revenues. Imagine if ELI-200 is FDA-approved and commercialized. ELTP's PPS would act accordingly and open the doors to more opportunities and exposure to attract business partners or invite a buyout candidate.

Cheers!

More BS("Big Surges") to come as each passing month gets us closer to Elite's Independence Day in July. Get ready for the fireworks, folks.

Cheers!

Nice close, guys!

Cheers!

Nice to hear your prognosis, Doc. As we get closer to July, we might see some "trigger happy" investors target ELTP as she pulls out of her drought. It will pouring pennies to a flash flood of dollars. Then, the crash of lightning-and-thunder, and we uplist.

Cheers!

Thank, God, I got out in time. Value-wise, AMBS needs to go back to sub-pennies.

Cheers!

Waiting to say the Elite "Cheers!".

Cheers!

Yup, loose lips sink ships. Run silent, run deep.

Cheers!

Lol, this does not make sense. Please explain.

Cheers!

Good luck to you, too!

Cheers!

Agreed! This is no typical OTC company. Hakim is focused on building the fundamentals, and not manipulating the share structure. For crying out loud, we are making steady, record-breaking revenues, which is a rarity for penny stocks. Accumulate at will because ya'll know Aqua is still buying.

Cheers!

Sold out last year. Just watching how low AMBS would go. Thus far, Gerald's inexperience in running a biotech is showing by running it to the ground with toxic financing and share structure. Shareholders deserve a CEO that has practical business plan that could at least generate some income to defer the immense costs in R & D.

Cheers!

Calling for 2-cents...

Cheers!

If you do the math,

Revenue gains + Non-ADT drug pipeline + ELI product line + New patents + FDA-approvals = $$$,$$$,$$$,$$$.

Cheers!

Nothing can stop us now, baby!

Cheers!

I wonder if Epic is on Hakim's mind for his plans to uplist in the future. I have not forgotten the unique partnerships we had when JT was CEO.

Cheers!

Pinch my butt, given that Elite continues to make steady, record-breaking revenues, it only makes sense The company is building its cash reserves despite the burning of cash in R & D and in operations. Elite has a history of merging (eg. Mikah).

Cheers!

Agreed! I think after the FDA-approval, 90-cents is conservative for starters. We still have that 97-cents wall to knockout before we could start thinking about a higher PPS breakout. But with strong revenues and net profit gains, it would sure pack a punch to knock the wall down.

Cheers!

The day of reckoning in about a couple months for Elite as we bid "A-L-O-O-O-O-O-O-O-H-A-H-A" to March Madness and look forward to big fireworks show when the FDA-approval on ELI-200 would be decided.

Cheers!

Call for 2-cents.

Cheers!

From my perspective, ELTP took a few steps back for the eventual touchdown pass. The ELI product line is our game changer.

Cheers!